- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05656963
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
July 17, 2023 updated by: Yipeng Liu
Influence Factors and Preliminary Mechanism of High Incidence of Thrombotic Events in Patients With Idiopathic Membranous Nephropathy and Diabetes Kidney Disease
Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
According to the results of renal biopsy, the patients were divided into three groups: membranous nephropathy group (MN), non-membranous nephropathy group (non-MN) and diabetes kidney disease group (DKD).
Collect the basic data and TEG test results of the enrolled patients.
(1) ① According to TEG results, the enrolled patients were divided into two groups: hypercoagulable group (CI > 3) and non-hypercoagulable group (CI ≤ 3).
The basic data and related laboratory indicators of the two groups were compared - to explore the influencing factors of hypercoagulable (objective X); ② Compare the parameters related to TEG and coagulation routine between MN group and non-MN group, DKD group and non-MN group respectively - find out the coagulation index (target Y) of the difference between groups; ③ Build regression models for different target Y - explore the influencing factors of grouping variables (MN vs non MN or DKD vs non MN) on Y after adjusting other covariates; (2) ① According to whether the patients in the group had thrombotic events or not, all the patients in the group with thrombotic events were divided into MN thrombotic events group and non-MN thrombotic events group according to pathological diagnosis, and the TEG, coagulation and other related laboratory results and basic data between the two groups were compared (explore the unique factors and processes that affect the occurrence of thrombotic events in MN group compared with non-MN group); ② According to whether the patients in the MN group who were hospitalized for many times had thrombotic events, the patients were divided into the MN group with thrombotic events and the MN group without thrombotic events.
The TEG, coagulation and other related laboratory results and basic data between the two groups were compared (to explore the factors and processes that affect the occurrence of thrombotic events in the MN group).
Study Type
Observational
Enrollment (Estimated)
741
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Qianfoshan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All patients who were diagnosed as primary glomerular disease by renal puncture biopsy and diabetes renal disease by clinical diagnosis and underwent thromboelastography (TEG) examination at the same time were newly treated patients and were not treated with hormone and other immunosuppressants.
Description
Inclusion Criteria:
- Primary glomerular disease patients with renal biopsy results (without hormone or immunosuppressive therapy) and patients with clinical diagnosis of diabetes kidney disease;
- Age 18-70;
- The liver function is normal.
Exclusion Criteria:
- Other secondary kidney diseases except diabetes; Acute renal injury; Chronic kidney disease stage 5;
- There are risk factors of hypercoagulability, such as acute infection, recent trauma, surgery or cancer, pregnancy;
- Anticoagulant and antiplatelet drugs were given within one week;
- Plasma infusion, plasma exchange or hemodialysis within one month;
- There is a history of thrombotic disease or hemorrhagic disease before renal puncture;
- Participated in other clinical studies within three months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Idiopathic membranous nephropathy
Patients with idiopathic membranous nephropathy proved by renal biopsy
|
The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
|
Non-Idiopathic membranous nephropathy
Other primary glomerular diseases except membranous nephropathy
|
The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
|
Diabetic kidney disease
Patients with clinical diagnosis of diabetes and kidney disease
|
The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Factors influencing the high incidence of thrombotic events in patients with membranous nephropathy and diabetic nephropathy
Time Frame: 2021-2024
|
Collect the basic data of the enrolled patients, including admission blood pressure, smoking, drinking history, the use of statins, anticoagulants and antiplatelet drugs, and blood test indicator.
All indicators for inclusion in the analysis are presented in full by subgroup.
① the enrolled patients were divided into two groups according to TEG results: hypercoagulable group (CI > 3) vs non hypercoagulable group (CI ≤ 3).
The basic data and related laboratory parameters of the two groups were compared to explore the influence of hypercoagulability factors (AIM X); ② Comparison of TEG and coagulation routine related parameters between MN and non MN group, DKD and non MN group - to find the coagulation indexes (target Y) that differ in TEG and coagulation routine between groups; ③ Regression models were constructed separately for different targets Y - to explore the influence of grouping variables (MN vs non MN or DKD vs non MN) on y after adjusting for other covariates;
|
2021-2024
|
Specific link between high incidence of thrombotic events in patients with membranous nephropathy and diabetic nephropathy
Time Frame: 2021-2024
|
① Based on collecting whether all the patients enrolled in multiple hospitalizations had thrombotic events, all the patients enrolled with thrombotic events were divided into MN with thrombotic events group and non MN with thrombotic events group according to the pathological diagnosis, and relevant assay results such as TEG, coagulation and basic data were compared between the two groups (to explore the specific factors and processes influencing the occurrence of thrombotic events specifically in the MN group compared to the non MN group); ② Based on whether thrombotic events occurred in patients within the Mn group enrolled in multiple hospitalizations, patients were divided into Mn with thrombotic events and Mn without thrombotic events groups, and relevant laboratory results and basic data such as TEG and coagulation were compared between the two groups (to explore factors and processes influencing the occurrence of thrombotic events in patients within the MN group).
|
2021-2024
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Yipeng Liu, Qianfoshan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Estimated)
October 30, 2023
Study Completion (Estimated)
January 31, 2024
Study Registration Dates
First Submitted
November 24, 2022
First Submitted That Met QC Criteria
December 7, 2022
First Posted (Actual)
December 20, 2022
Study Record Updates
Last Update Posted (Actual)
July 18, 2023
Last Update Submitted That Met QC Criteria
July 17, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Embolism and Thrombosis
- Nephritis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Diabetic Nephropathies
- Thromboembolism
- Glomerulonephritis
- Glomerulonephritis, Membranous
Other Study ID Numbers
- YXLL-KY-2022(102)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathies
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)TerminatedDiabetic Nephropathy | Diabetic Kidney DiseaseUnited States, Australia, Bulgaria, France, Germany, Hong Kong, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
-
University of MilanActive, not recruitingDiabetic Nephropathy Type 2Italy
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
Clinical Trials on Grouping based on previous laboratory results, no intervention.
-
Yipeng LiuActive, not recruiting
-
Yipeng LiuActive, not recruiting
-
University of Sao Paulo General HospitalUnknown
-
Aristotle University Of ThessalonikiRecruitingMetalloproteinase SNPs -1575 G/A MMP-2, 836 A/G MMP-9 and -77 A/G MMP-13 and Risk for Developing Knee Osteoarthritis in Greek PopulationGreece
-
Istanbul University - Cerrahpasa (IUC)Completed
-
American Medical AssociationJohns Hopkins University; University of California, San Francisco; University... and other collaboratorsUnknownPhysician Work Motivation
-
Swiss SOS Study GroupUniversitätsklinik für Neurochirurgie, Inselspital Bern; Département des Neurosciences... and other collaboratorsTerminatedStroke | Cognitive Impairment | Subarachnoid Hemorrhage | Delayed Cerebral Ischemia | Complication | Cognitive Deficit | Cognitive Deterioration | Cognitive Deficits Following Cerebral InfarctionSwitzerland
-
Erasme University HospitalUniversity of Liege; Universitair Ziekenhuis Brussel; University Hospital, Lille and other collaboratorsCompletedBacteriuria | Urinary Tract Infections | Kidney Transplantation | Asymptomatic BacteriuriaBelgium, France
-
Maastricht University Medical CenterRadboud University Medical Center; UMC Utrecht; Academisch Medisch Centrum -... and other collaboratorsEnrolling by invitationCOVID-19 | Long COVID | Post COVID-19 ConditionNetherlands
-
University of BernCompletedDepression Moderate | Depression MildSwitzerland